Stay updated on HERV-W Antagonist GNbAC1 Clinical Trial

Sign up to get notified when there's something new on the HERV-W Antagonist GNbAC1 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the HERV-W Antagonist GNbAC1 Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-06-13T21:44:20.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or modification in the data related to the clinical trial assessing the HERV-W Env Antagonist GNbAC1 for efficacy in MS (CHANGE-MS). This change may be significant for individuals monitoring medical and healthcare-related publications and documentation.
    Difference
    0.2%
    Check dated 2024-06-06T14:21:37.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as the use of contraception, diagnosis according to the 2010 revised McDonald criteria, and disease activity. Previously, this section only indicated that no information was provided.
    Difference
    13%
    Check dated 2024-05-22T20:30:11.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    2%
    Check dated 2024-04-30T22:39:55.000Z thumbnail image

Stay in the know with updates to HERV-W Antagonist GNbAC1 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the HERV-W Antagonist GNbAC1 Clinical Trial page.